UNH - UnitedHealth Group Incorporated

NYSE - NYSE Delayed Price. Currency in USD
+4.95 (+1.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
Previous Close289.94
Bid0.00 x 4000
Ask296.00 x 800
Day's Range292.50 - 297.03
52 Week Range187.72 - 306.71
Avg. Volume6,202,043
Market Cap279.668B
Beta (5Y Monthly)0.72
PE Ratio (TTM)20.64
EPS (TTM)14.29
Earnings DateJul 16, 2020 - Jul 20, 2020
Forward Dividend & Yield4.32 (1.49%)
Ex-Dividend DateMar 13, 2020
1y Target Est327.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
8% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 5 Digital Health Stocks to Soar Amid Coronavirus Crisis

    5 Digital Health Stocks to Soar Amid Coronavirus Crisis

    The coronavirus pandemic has helped digital health surge like never before. With virtual visits increasing on a daily basis, we have five stocks that are set to gain.

  • Hedge Funds Have Never Been This Bullish On UnitedHealth Group (UNH)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On UnitedHealth Group (UNH)

    In this article we will check out the progression of hedge fund sentiment towards UnitedHealth Group Inc. (NYSE:UNH) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and […]

  • MarketWatch

    Dow flat in spite of gains in shares of UnitedHealth, Travelers

    DOW UPDATE The Dow Jones Industrial Average is up Friday afternoon with shares of UnitedHealth and Travelers leading the way for the price-weighted average. Shares of UnitedHealth (UNH) and Travelers (TRV) are contributing to the index's intraday rally, as the Dow (DJIA) is trading 7 points (0.

  • 2021 health insurance rates are coming out despite 'unprecedented uncertainty'
    Yahoo Finance

    2021 health insurance rates are coming out despite 'unprecedented uncertainty'

    Insurance companies are proposing rates for 2021. With the Covid-19 crisis, there's little clarity about the future, making it an unprecedented situation for the industry and consumers.

  • Investopedia

    UnitedHealth Stock Nears Major Breakout

    UnitedHealth stock has recovered from the first quarter sell-off and now looks ready to break out above 2018 resistance.

  • UnitedHealth, Microsoft's New Mobile App to Help Trace Coronavirus

    UnitedHealth, Microsoft's New Mobile App to Help Trace Coronavirus

    UnitedHealth (UNH) and Microsoft will jointly launch a mobile application that will create a safe work ambience for employees returning to work by screening them for COVID-19 symptoms.

  • Business Wire

    Study Finds Seniors with COVID-19 Taking Hypertension Medication at Lower Risk of Hospitalization, Clinical Trial to Follow Immediately

    A study completed by UnitedHealth Group (NYSE: UNH) with the Yale School of Medicine found that older COVID-19 patients with hypertension taking angiotensin-converting enzyme (ACE) inhibitors had a lower risk of COVID-19 hospitalization. A pragmatic clinical trial will be a critical next step.

  • Microsoft Teams Up With UnitedHealth To Help Coronavirus Recovery; Both Near All-Time Highs
    Investor's Business Daily

    Microsoft Teams Up With UnitedHealth To Help Coronavirus Recovery; Both Near All-Time Highs

    As UnitedHealth and Microsoft team up to help people get back to work and speed the coronavirus recovery, UNH stock and MSFT stock near buy points.

  • Microsoft (MSFT), UnitedHealth Partner on Return-to-Work App

    Microsoft (MSFT), UnitedHealth Partner on Return-to-Work App

    Microsoft (MSFT) ties up with UnitedHealth Group (UNH) to launch ProtectWell Protocol and App to aid employers in bringing employees back to workplace in a secure setting.

  • Ray Dalio Picks Up These 3 “Strong Buy” Stocks

    Ray Dalio Picks Up These 3 “Strong Buy” Stocks

    COVID-19's impact has been crippling, but something positive may come from the pandemic. Billionaire Ray Dalio said in a live LinkedIn interview that in terms of the broader historical context, the recent economic downturn should be “relatively brief," and could spur significant societal progress. This would include a worldwide “restructuring” lasting approximately three to five years.“I know that’s a long time, but it’s not forever. The human capacity to adapt and invent and come out of this is much greater,” Dalio commented. He added, “I think we should be very excited about the new future. We’re now in a wonderful revolution in terms of the capacity to think and use that in a way. I would say that is absolutely the most treasured thing in the future.”Still making sure to account for the unknowns, Dalio has been diversifying his investments across geographic locations, asset class and currencies throughout the ongoing public health crisis. Looking to Dalio for investing inspiration, we used TipRanks’ database to find out if three stocks the billionaire recently added to the fund represent compelling plays. According to the platform, the analyst community believes they do, with all of the picks earning “Strong Buy” consensus ratings. Let’s jump right in.Philip Morris International (PM)Cigarette and tobacco manufacturing company Philip Morris has become known as a “sin stock." However, regardless of its product portfolio, Dalio sees plenty of upside in store.Recently, the billionaire’s fund acquired a new position in PM, snapping up 67,447 shares. The value of this new addition? More than $4.9 million.Turning now to the analysts, the stock boasts a strong fan base, which includes Piper Sandler’s Michael Lavery. He doesn’t dispute the fact that there are some headwinds facing the company. “PM expects near-term iQOS new user acquisition to be about 50% lower than it originally planned due to social distancing measures that have shut iQOS stores and made it harder to engage with consumers,” Lavery stated.That being said, the company has already surpassed Lavery’s expectations, which were cut to near-zero. The analyst even says that if PM can maintain the pace of its customer acquisition, there could be upside to his estimates. The analyst added, “We expect HeatStick volume growth of 20% in 2020E (1Q20: +45%) and believe 90-100 billion sticks in 2021 is still achievable.”While lower duty-free volumes and down-trading in Indonesia could take a toll on second quarter EPS, Lavery remains optimistic. “We remain bullish on PM's strong long-term outlook, and we expect nicotine demand to remain resilient near-term (particularly in times of personal stress),” he explained.It should also be noted that PM has had to grapple with patent infringement claims from British American Tobacco (BAT) and a transactional currency hit. Speaking to the first issue, Lavery said, “We reviewed BAT's six patents named in its U.S. complaint, and it is difficult to handicap an outcome, but a third-party reviewer of patents generally did not give BAT's relevant ones here very high marks.”As for the latter, Lavery points out that about $100 million of the currency hit in the first quarter of 2020 was driven by the revaluation of euro or dollar denominated payables in markets like Russia, but he doesn’t foresee another event of this magnitude happening again.Based on all of the above, Lavery kept an Overweight rating on the stock. He did reduce the price target from $98 to $95, but this still implies shares could climb 40% higher in the next year. (To watch Lavery’s track record, click here) Judging by the consensus breakdown, other analysts are in agreement. 7 Buys and 2 Holds add up to a Strong Buy consensus rating. In addition, the $83.56 average price target brings the upside potential to 23%. (See Philip Morris stock analysis on TipRanks)UnitedHealth Group (UNH)Hoping to help people live healthier lives and make the healthcare system work more efficiently, UnitedHealth Group offers a wide range of healthcare products and insurance services. While the late-March acceleration of the COVID-19 pandemic resulted in a somewhat lackluster quarter, Dalio believes the company’s future is bright.To this end, Bridgewater went in on UNH. In a purchase valued at $5,481,000, Dalio’s hedge fund scooped up 21,977 shares.Five-star analyst Michael Wiederhorn agrees that UNH is moving on to bigger and better things, noting that its Q1 performance was relatively solid. “Overall, UNH produced strong results and seems well-positioned to navigate the COVID pandemic due to a relatively stable top-line, a diversified business mix and a dominant position across its businesses.”Wiederhorn tells investors that management thinks the slowdown in non-COVID-irelated utilization, which was driven by highly constrained elective care and will be offset by the late-year pent-up utilization, will have a significant impact on MCR in the second quarter. As a result, despite some uncertainty surrounding COVID-19's impact, UNH maintained its full year 2020 EPS guidance of $16.25-$16.55.Adding to the good news, Wiederhorn argues that its Optum segment has a strong standing within the market. Expounding on this, he noted, “Trends at Optum remained solid, and management did note that even OptumHealth should be positioned to hold up relatively well due to its reliance on risk-based contracts, accounting for two thirds of revenues. Both OptumRx and OptumInsight have strong pipelines (though the timing of meetings was disrupted) with the latter of particular interest as companies look to improve the economics and delivery of healthcare.”Even though commercial enrollment could be hampered by elevated levels of unemployment, higher Medicaid should partially offset this. Additionally, UNH is in the early stages of pricing and benefit design for 2021, with its plans possibly including pricing for COVID-19 testing and a potential vaccine.Bearing this in mind, Wiederhorn maintained an Outperform call and $343 price target. Should this target be met, a twelve-month gain of 18% could be in the cards. (To watch Wiederhorn’s track record, click here)Turning now to the rest of the Street, other analysts also like what they’re seeing. With 12 Buys and 2 Holds, the word on the Street is that UNH is a Strong Buy. At $326.23, the average price target indicates 12% upside potential. (See UnitedHealth stock analysis on TipRanks)Accenture PLC (ACN)Dalio’s third recent addition, Accenture, provides management and technology consulting services and solutions to help its clients, which inhabit almost every industry, create lasting value. With the company relying on a new strategy, Dalio thinks it has set itself up for success.Not wanting to miss out on a compelling opportunity, Bridgewater pulled the trigger on 27,763 shares, giving it a new position in ACN. Looking at the value of the new holding, it comes in at more than $4.5 million.When it comes to the analysts, they are also singing the company’s praises. Writing for BNP Paribas, analyst Ben Castillo-Bernaus argues that COVID-19's disruption has presented investors with an opportunity to buy a “high-quality” IT service company, with ACN trading well below historical five-year average EBIT multiples.“Accenture remains ‘best in class’ and the recent weakness is an opportunity to gain a position in this IT Services global leader delivering 40% returns on capital,” Castillo-Bernaus stated. He added, “Accenture has been a pioneer in developing ‘the New’ with 65% of revenues now coming from high growth Digital, Cloud and Security services.”As for what makes the company so successful and allows it to continuously take market share, Castillo-Bernaus points to its investments in new technologies and growth areas. To back up this conclusion, the analyst cites its EUR1 billion investment in training each year and EUR800 million investment in R&D all while delivering margin improvements every year. On top of this, ACN conducts smaller-scale M&A, with it working alongside the companies before an acquisition to limit any potential deal failures.Castillo-Bernaus also noted, “We believe Accenture has customers that spend more than $100 million annually, with 98% of Accenture’s top 100 clients having been clients for more than five years. These ‘sticky’ relationships help Accenture maintain high margins and high returns as Accenture has a high number of ‘sole source’ wins where it does not even see competition in RFPs.”That being said, the company has started using a new approach. It will now organize itself by Strategy & Consulting, Interactive, Technology and Operations instead of by verticals, and the results will be reported geographically for these segments. “We believe it is too early to tell what kind of impact these changes will have, but Accenture has a positive track record of occasionally tweaking its growth strategy in order to best deliver on the opportunities ahead,” Castillo-Bernaus commented.It should come as no surprise, then, that Castillo-Bernaus joined the bulls. Along with an Outperform rating, he initiated coverage by setting a $215 price target. This target conveys the analyst’s confidence in ACN's ability to surge 17% in the next twelve months.In general, other Wall Street analysts have also been impressed. ACN’s Strong Buy consensus rating breaks down into 13 Buys and 2 Holds assigned in the last three months. However, the $195.29 average price target suggests modest upside potential of 6%. (See Accenture stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • Microsoft, UnitedHealth Launch Back-to-Work Covid-19 Screening App

    Microsoft, UnitedHealth Launch Back-to-Work Covid-19 Screening App

    Microsoft Corp. (MSFT) and UnitedHealth Group (UNH) have teamed up to roll out an everyday free screening app for coronavirus symptoms as more and more employers are planning to reopen their businesses and are subject to stringent health requirements.Th app, also known as ProtectWell, allows employers to offer workers a simple screening tool designed for everyday use. The smartphone app includes an AI-powered health care bot that asks users a series of questions to screen for Covid-19 symptoms or exposure. If risk of infection is indicated, employers can direct their employees to a streamlined Covid-19 testing process that enables closed-loop ordering and reporting of test results directly back to employers.“As businesses begin to reopen, employers will need to monitor and manage their workforce for Covid-19 symptoms to help ensure those at risk of spreading the virus stay home until cleared by medical providers,” said Judson Althoff, Microsoft’s executive vice president of worldwide commercial business.The screening app uses the clinical and data analytics of UnitedHealth combined with Microsoft’s artificial intelligence and analytics capabilities. The smartphone app, which will be powered by Microsoft Azure, will be available to all U.S. employers at no charge. Microsoft said it plans to deploy ProtectWell for its U.S.-based employees.For privacy protection, UnitedHealth will maintain control over protected health care data and will manage opt-in and consent requirements needed from app users. Microsoft will not have access to identifiable information shared via the app.Shares in Microsoft have soared 35% in the past two months and were trading at $183.16 on Friday. UnitedHealth shares have recovered after declining to a multi-year low on March 23 and are now trading around their start-of-year level at $290.96.Five-star analyst Keith Weiss at Morgan Stanley reiterated the Buy rating on Microsoft’s stock with a $198 price target, saying that he forecasts the company to generate double-digit top-line growth in the near term.“Based on the focus from senior management and strong secular tailwinds behind Security spending, we expect these installed base and data advantages to lead Microsoft into new markets like DevSecOps, IoT Security, and Data Privacy,” Weiss wrote in a report to investors.TipRanks data shows that overall Wall Street analysts are almost unanimously bullish on Microsoft’s stock. Twenty-two out of the 23 analysts have Buy ratings and 1 has a Hold rating adding up to a Strong Buy consensus. The $198.67 average price target provides investors with 8.5% upside potential in the shares in the coming 12 months. (See Microsoft stock analysis on TipRanks).Related News: Microsoft Buys Metaswitch For Cloud-Based Telecoms Move, 5G Expansion Apple is Said to Snap Up Startup NextVR For Virtual Reality Content; Top Analyst Sees Buying Opportunity Taiwan Semi Has Not Received Any Assurance On US License For Huawei Tech Sale More recent articles from Smarter Analyst: * Regeneron To Repurchase $5 Billion Stake From Sanofi   * Gates Foundation Buys Up Amazon, Apple, Twitter Stock; Trims Berkshire Hathaway Stake * Earnings: RBC Forecasts Choppy Results For Dell This Thursday * Salesforce Earnings Preview: Five-Star Analyst Bullish Into Print

  • Humana, One Medical Clear Buy Points; Are These Three Next?
    Investor's Business Daily

    Humana, One Medical Clear Buy Points; Are These Three Next?

    Humana and One Medical cleared buy points last week. Will UnitedHealth be the next managed-care stock to break out?

  • MarketWatch

    Dow jumps nearly 50 points on gains in Walt Disney, Home Depot stocks

    DOW UPDATE Led by strong returns for shares of Walt Disney and Home Depot, the Dow Jones Industrial Average is climbing Friday afternoon. Shares of Walt Disney (DIS) and Home Depot (HD) are contributing around a quarter of the blue-chip gauge's intraday rally, as the Dow (DJIA) was most recently trading 48 points (0.

  • UnitedHealthcare Ties Up to Improve Eye Health of Members

    UnitedHealthcare Ties Up to Improve Eye Health of Members

    UnitedHealth Group's (UNH) UnitedHealthcare business collaborates with GlassesUSA.com for providing improved eye care to its eligible members.

  • Insider Monkey

    Is UnitedHealth Group (UNH) A High Quality Stock To Own?

    Fiduciary Management, Inc recently released its Q1 2020 Investor Letter, a copy of which you can download below. The FMI Large Cap Fund posted a return of -23.0% for the quarter, underperforming its benchmark, the S&P 500 Index which returned -19.60% in the same quarter. You should check out Fiduciary Management’s top 5 stock picks […]

  • Business Wire

    UnitedHealth Group and Microsoft Collaborate to Launch ProtectWell™ Protocol and App to Support Return-to-Workplace Planning and COVID-19 Symptom Screening

    UnitedHealth Group (NYSE: UNH) and Microsoft Corp. (Nasdaq: MSFT) have joined forces to launch ProtectWell™, an innovative return-to-workplace protocol that enables employers to bring employees back to work in a safer environment. ProtectWell™ helps employees determine they are safe to go to work, co-workers know their colleagues have been screened, and employers feel confident that their workplace is ready to do business. ProtectWell™ incorporates Centers for Disease Control and Prevention (CDC) guidelines and the latest clinical research to limit the spread of COVID-19 by screening employees for symptoms and establishing guidelines to support the health and safety of the workforce and workplace.

  • Top 5 Buys of Ray Dalio's Bridgewater in the 1st Quarter

    Top 5 Buys of Ray Dalio's Bridgewater in the 1st Quarter

    The $165 billion hedge fund releases portfolio in a coronavirus-driven landscape Continue reading...

  • Dow Jones Reverses Higher After Bullish Test Of Support; 4 Chip Stocks Lead Nasdaq 100
    Investor's Business Daily

    Dow Jones Reverses Higher After Bullish Test Of Support; 4 Chip Stocks Lead Nasdaq 100

    The Dow Jones reversed higher Thursday after finding support at its 50-day moving average. The Nasdaq was boosted by strength in semiconductor stocks.

  • MarketWatch

    American Express, UnitedHealth share gains lead Dow's nearly 300-point rally

    DOW UPDATE Shares of American Express and UnitedHealth are trading higher Thursday afternoon, leading the Dow Jones Industrial Average rally. Shares of American Express (AXP) and UnitedHealth (UNH) have contributed to the blue-chip gauge's intraday rally, as the Dow (DJIA) is trading 296 points, or 1.

  • MarketWatch

    Dow on pace for its biggest intraday comeback in 2 months as financials and health-care stocks burst higher

    The Dow Jones Industrial Average late-day Thursday was trading higher, putting the index on track for its biggest comeback in about 8 weeks amid the COVID-19 pandemic. The Dow was up 244 points, or 1.1%, at 23,486, following a skid that saw it lose as many as 458 points at its intraday nadir at 22,789.62, or down nearly 2%. If the benchmark manages to end higher for the day it will mark the biggest intrasession rebound since March 19, according to Dow Jones Market Data. Gains were being driven by an nearly 7% advance in American Express Co. and a 4.4% gain in shares of UnitedHealth Group Inc., which were helping to lead the charge. The S&P 500 index was up 0.4% at 2,832, powered by a gain in the financials sector , a rally in materials names and health care . The technology-laden Nasdaq Composite Index was trading at around unchanged at 8,870, but well off its lows at 8,705.25.

  • Top Research Reports for UnitedHealth, AT&T & Netflix

    Top Research Reports for UnitedHealth, AT&T & Netflix

    Top Research Reports for UnitedHealth, AT&T; & Netflix